{"links":{"html":"https://www.erudio.com/reports/enco-braf-nct04526782","json":"https://www.erudio.com/reports/enco-braf-nct04526782.json","markdown":"https://www.erudio.com/reports/enco-braf-nct04526782.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"enco-braf-04526782"}},"request":"https://www.erudio.com/contact?report=enco-braf-04526782"},"offer":{"cited_commentary_sources":20,"verified_hcp_statements":36,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":750,"identity_verified_people":11,"optional":true,"price_per_verified_person_usd":15,"price_usd":165,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"enco-braf-nct04526782"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=enco-braf-04526782","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/enco-braf-nct04526782","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-29T08:19:18.813750Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":15,"no_commentary_found":0},"aspects":[{"claim_count":4,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":3,"title":"Primary endpoint: Objective response rate"},{"claim_count":3,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes[0]","source_count":2,"title":"Secondary endpoint: Duration Response Rate"},{"claim_count":7,"coverage":"discussed","id":"T3","registry_field":"outcomesModule.secondaryOutcomes[1]","source_count":5,"title":"Secondary endpoint: Progression-free Survival"},{"claim_count":5,"coverage":"discussed","id":"T4","registry_field":"outcomesModule.secondaryOutcomes[2]","source_count":4,"title":"Secondary endpoint: Overall Survival"},{"claim_count":3,"coverage":"discussed","id":"T5","registry_field":"outcomesModule.secondaryOutcomes[3]","source_count":3,"title":"Secondary endpoint: Incidence, type and severity of adverse events"},{"claim_count":5,"coverage":"discussed","id":"T6","registry_field":"conditionsModule","source_count":3,"title":"Population and setting"},{"claim_count":4,"coverage":"discussed","id":"T7","registry_field":"armsInterventionsModule.armGroups","source_count":2,"title":"The comparison"},{"claim_count":6,"coverage":"discussed","id":"T8","registry_field":"outcomesModule","source_count":5,"title":"Safety and tolerability"},{"claim_count":3,"coverage":"discussed","id":"T9","registry_field":"designModule","source_count":3,"title":"Design and conduct"},{"claim_count":6,"coverage":"discussed","id":"A1","source_count":6,"title":"Comparative positioning versus dabrafenib plus trametinib and PHAROS"},{"claim_count":3,"coverage":"discussed","id":"A2","source_count":1,"title":"Sequencing, smoking status and TP53"},{"claim_count":4,"coverage":"discussed","id":"A3","source_count":4,"title":"Research access, enrollment and hoped-for treatment access"},{"claim_count":7,"coverage":"discussed","id":"A4","source_count":4,"title":"Earlier encorafenib–binimetinib evidence in BRAF V600E NSCLC"},{"claim_count":6,"coverage":"discussed","id":"A5","source_count":5,"title":"Treatment-option and standard-of-care language"},{"claim_count":3,"coverage":"discussed","id":"A6","source_count":1,"title":"Practice experience and an individual response example"}],"counts":{"cited_sources":20,"claims_by_expression_type":{"comparison":5,"experience":4,"interpretation":7,"opinion":10,"primary_context":1,"question":1,"restatement":6,"uncertainty":2},"claims_by_kind":{"source_observation":36},"clinician_statements":14,"evidence_units":36,"findings":5,"organisational_accounts":2,"people_cited":13,"people_identity_verified":11,"people_total":13,"screened_sources":35,"verified_claims":36},"depth":"standard","findings_index":[{"id":"F1","structure":{"claims":5,"claims_by_group":{"comparisons":4,"experience":0,"questions":1,"restated":0,"views":0},"has_counterview":true,"limitations":3,"links":{"context":0,"support":5},"ma_question":true,"named_voices":4,"passages":5,"sources":5,"sources_by_kind":{"commentary":5}},"title":"The PFS discrepancy complicates comparative positioning"},{"id":"F2","structure":{"claims":7,"claims_by_group":{"comparisons":1,"experience":3,"questions":0,"restated":3,"views":0},"has_counterview":false,"limitations":4,"links":{"context":1,"support":7},"ma_question":true,"named_voices":6,"passages":8,"sources":6,"sources_by_kind":{"commentary":6}},"title":"Low fever is attractive, but does not remove consequential toxicity"},{"id":"F3","structure":{"claims":5,"claims_by_group":{"comparisons":0,"experience":0,"questions":2,"restated":1,"views":2},"has_counterview":false,"limitations":3,"links":{"context":0,"support":5},"ma_question":true,"named_voices":2,"passages":2,"sources":2,"sources_by_kind":{"commentary":1,"media":1}},"title":"Sequencing and biomarker selection remain conditional"},{"id":"F4","structure":{"claims":6,"claims_by_group":{"comparisons":0,"experience":1,"questions":0,"restated":2,"views":3},"has_counterview":false,"limitations":2,"links":{"context":1,"support":6},"ma_question":true,"named_voices":3,"passages":3,"sources":3,"sources_by_kind":{"commentary":2,"media":1}},"title":"Updated response durability drives enthusiasm without proving equivalence across lines"},{"id":"F5","structure":{"claims":13,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":1,"views":12},"has_counterview":false,"limitations":4,"links":{"context":0,"support":13},"ma_question":true,"named_voices":7,"passages":12,"sources":10,"sources_by_kind":{"commentary":10}},"title":"Option and standard language coexist with distinct research-access concerns"}],"medical_affairs_question":"How should Medical Affairs explain clinical positioning, low-fever tolerability and sequencing without turning indirect evidence into superiority, exploratory factors into treatment rules, or study access into routine availability?","sections":{"analysis":[{"id":"section-1","level":2,"title":"The PFS discrepancy complicates comparative positioning"},{"id":"section-2","level":2,"title":"Low fever is attractive, but does not remove consequential toxicity"},{"id":"section-3","level":2,"title":"Sequencing and biomarker selection remain conditional"},{"id":"section-4","level":2,"title":"Updated response durability drives enthusiasm without proving equivalence across lines"},{"id":"section-5","level":2,"title":"Option and standard language coexist with distinct research-access concerns"},{"id":"section-6","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, non randomized, parallel, phase2","trial_dimensions":[{"findings":[{"id":"F2","shared_claims":2},{"id":"F4","shared_claims":2}],"id":"T1","label":"Primary endpoint: Objective response rate"},{"findings":[{"id":"F2","shared_claims":1},{"id":"F4","shared_claims":2}],"id":"T2","label":"Secondary endpoint: Duration Response Rate"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F2","shared_claims":2},{"id":"F4","shared_claims":3}],"id":"T3","label":"Secondary endpoint: Progression-free Survival"},{"findings":[{"id":"F2","shared_claims":2},{"id":"F4","shared_claims":3}],"id":"T4","label":"Secondary endpoint: Overall Survival"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":2}],"id":"T5","label":"Secondary endpoint: Incidence, type and severity of adverse events"},{"findings":[{"id":"F4","shared_claims":4},{"id":"F5","shared_claims":1}],"id":"T6","label":"Population and setting"},{"findings":[{"id":"F4","shared_claims":4}],"id":"T7","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":5}],"id":"T8","label":"Safety and tolerability"},{"findings":[{"id":"F2","shared_claims":1},{"id":"F4","shared_claims":1},{"id":"F5","shared_claims":1}],"id":"T9","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-29T08:19:18.813750Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-29T08:29:47Z","record_hash":"69ad3588a98ff8090169aee640372590853a8afe8933109e35c64f6159204613","release_hash":"60f424a19ecc0137e30d39024cb310dac57eccfa63d1854f42656d640e8cd0a3","report_id":"erudio-nct04526782","run_id":"74a51cd3-52a6-4228-99a9-011df24dd099","schema_version":"5.0","slug":"enco-braf-04526782","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"ENCO-BRAF asks how well encorafenib plus binimetinib treats metastatic BRAF V600E-mutant non-small cell lung cancer. An X poster welcomes the treatment option, while comparative positioning draws questions in an X thread. An X poster favors tolerability; progression-free survival comparisons draw scrutiny in X discussion. A YouTube interview speaker leaves sequencing and biomarker selection unresolved. The sources reviewed for this edition place the trial’s main results at ESMO 2024.","meta_description":"35 sources screened · 36 verified statements (14 from clinicians verified by NPI or staff page) from 20 sources · 5 findings. Updated Oct 29, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-a35689b2b7dc3f4dc3d1"],"id":"F1","paraphrase":"An X thread asks what might explain differences in progression-free survival between studies of the combination.","publication_caveats":{"reason":"Publication caveats are not stated in the sources reviewed for this edition.","status":"not_set"},"source_channel":"x_thread","source_date":"2024-09-14","title":"The PFS discrepancy complicates comparative positioning"},{"cited_claim_ids":["claim-cead9df362a7871a19eb","claim-f87ede457a18a2ddd466"],"id":"F3","paraphrase":"A YouTube interview addresses questions about treatment order and the role of biomarkers in sequencing.","publication_caveats":{"reason":"Publication caveats are not stated in the sources reviewed for this edition.","status":"not_set"},"source_channel":"youtube","source_date":"2026-10-28","title":"Sequencing and biomarker selection remain conditional"}]},"publication":{"approved_at":"2026-10-29T08:29:47Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":35},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Not yet captured in this edition: a view on first-line combination efficacy and the immaturity of progression-free survival and response-duration follow-up.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","9 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","Nineteen of 37 original sources contain passages that were not fully assessed; additional relevant views may therefore be missing.","Discussion using other wording or leaving the trial unnamed may be absent, including treatment-decision commentary relevant to the same population.","The sources do not establish the prevalence of these views among HCPs. Reposts and source counts should not be interpreted as independent endorsements.","A full protocol and an exact-trial results publication were unavailable for this edition, limiting assessment of methods and reported outcomes against a complete study report.","Exact regulatory product information was unavailable. Approval, standard-of-care and access descriptions are presented as dated, attributed statements rather than independently confirmed jurisdictional conclusions.","Earlier combination studies, PHAROS, ENCO-BRAF results and practice anecdotes must remain separate; their figures do not form a pooled efficacy or safety estimate.","The October 2026 post and interview give different previously treated survival values, 37.5 and 35 months, without explaining the difference."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":18,"x_video":0,"youtube":2},"by_evidence_role":{"commentary":20},"count":20,"evidence_window":{"end":"2026-10-28","start":"2023-06-04"},"retrieval_snapshot":"2026-10-29T07:46:09.506380Z","timeline":[{"count":2,"week":"2023-W22"},{"count":3,"week":"2023-W23"},{"count":1,"week":"2023-W29"},{"count":1,"week":"2023-W41"},{"count":7,"week":"2024-W37"},{"count":1,"week":"2024-W39"},{"count":1,"week":"2026-W05"},{"count":1,"week":"2026-W43"},{"count":3,"week":"2026-W44"}],"undated_sources":0},"quote_policies":[{"id":"clinicaltrials:NCT04526782:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT04526782:context","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-hvybly7ak5rfumcoeda5r4mx-3m6nx7liq7k2p","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1665480085716058112:ad96fd32-a3a2-4048-8387-997c0f342b16","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1665481701802352641:56ce9ed3-f376-4b7e-8c8c-1b56c98228bd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1665726275602767872:9a39439b-7586-4bcb-887e-8bc6e1ab3462","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1665735968920313856:bdeb80b0-3af6-4b22-b43d-d1fc78c6d170","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1665815174022922241:7bb8abd8-9c9d-4e30-9c4f-7565c1b31f25","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1672228764527230977:bf6d782a-db59-4bce-b276-926a48e08dcc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1681868848956338177:510dba59-343b-46bb-9d94-c6225724b59b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1707324094679568386:dccf5b8a-f6e7-43ac-b2e2-2ea77a760c43","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1712371333420421128:3bad632d-5722-4ef8-9d17-b89f0ebed249","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1721268426059010115:fdea7e5e-bb7a-44d9-94d5-0dd84177ea6c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1832017564794319081:cca7e016-aad5-4d58-84f5-d1eef0497eed","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1834519659850108956:276f1eef-be03-497f-b941-a69bdc53d07a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1834853337700892751:f1a6a8d9-1ca7-4510-a184-11c9094ff196","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1834887770336006626:bd61b0cc-dac1-4a45-be2d-f6cfbab95c95","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1834888795205845500:a07bb0c5-66f3-4440-b743-43f8942d507f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1834889190724518153:2234287f-bec6-48e4-9bc1-aef6c9befade","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1834900678684074107:e6c3c3b7-9dda-439e-b747-fce1e0f03a94","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1834907658739921216:3a94e38c-800f-4f13-8264-00a4f45c44cd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1834945401817895240:d57424d5-3a9d-4daa-ae56-7a70e8735c5d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1835219662801387817:dd4a2a6a-e4d7-47a9-b58b-6c73363aed94","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1835341918655705509:eb7ad33c-333d-4ec3-a2b3-9cd28ea19c74","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1835741143495000065:bc5401a8-c069-44b0-86fc-b99ef0774cda","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1835802088284311678:1db5d339-e49c-4409-a251-8efddea9385c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1838571152161280348:ba55969d-ebc1-4b91-90ef-b715dcff5c95","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2016788456328802369:4273bce9-412e-4162-8e2f-83262ce05d7d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2039739949952450676:4f189904-ef52-45bf-8daf-ddc174b9675e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2097030402586116400:e23c40ea-7d93-4f22-926f-3ce981fbc357","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113276244506624163:c0bdcd40-0aa2-4424-843f-447e7098607c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113284987222896922:f0342fa2-bd14-4b00-8d8f-8efb649a0ac7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113509836478378117:31be8da8-6970-4f65-b143-56fb8006da1b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114633767788945644:fa71d3e9-44de-48c4-9517-577e4f9db839","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114709099585925211:caf0cb49-ca47-4da6-a5cb-ae1c86d5990f","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:4epch4zEy2Y","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:G5iNzrJNxB4","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":1,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":32,"x_video":0,"youtube":2},"by_evidence_role":{"commentary":35},"count":35,"evidence_window":{"end":"2026-10-28","start":"2023-06-04"},"retrieval_snapshot":"2026-10-29T07:46:09.506380Z","timeline":[{"count":2,"week":"2023-W22"},{"count":3,"week":"2023-W23"},{"count":1,"week":"2023-W25"},{"count":1,"week":"2023-W29"},{"count":1,"week":"2023-W39"},{"count":1,"week":"2023-W41"},{"count":1,"week":"2023-W44"},{"count":1,"week":"2024-W36"},{"count":10,"week":"2024-W37"},{"count":2,"week":"2024-W38"},{"count":1,"week":"2024-W39"},{"count":1,"week":"2025-W48"},{"count":1,"week":"2026-W05"},{"count":1,"week":"2026-W14"},{"count":1,"week":"2026-W37"},{"count":3,"week":"2026-W43"},{"count":4,"week":"2026-W44"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: encorafenib 75 mg","status":"unmapped"},{"reason":"Unmapped registry intervention: binimetinib 15 mg","status":"unmapped"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Non-small cell lung cancer","slug":"non-small-cell-lung-cancer"},{"reason":"Unmapped registry condition: BRAF V600E","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"ENCO-BRAF","aliases":["ENCO-BRAF","ENCOrafenib With Binimetinib in bRAF NSCLC","A Phase II Study of the BRAF Inhibitor Encorafenib in Combination With the MEK Inhibitor Binimetinib in Patients With BRAFV600E-mutant Metastatic Non-small Cell Lung Cancer"],"brief_title":"ENCOrafenib With Binimetinib in bRAF NSCLC","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Non Small Cell Lung Cancer","BRAF V600E"],"enrollment":{"count":119,"type":"ESTIMATED"},"interventions":[{"name":"Encorafenib 75 MG","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Binimetinib 15 MG","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT04526782","official_title":"A Phase II Study of the BRAF Inhibitor Encorafenib in Combination With the MEK Inhibitor Binimetinib in Patients With BRAFV600E-mutant Metastatic Non-small Cell Lung Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phase":["PHASE2"],"primary_completion_date":{"date":"2025-07-16","type":"ACTUAL"},"primary_endpoints":[{"description":"Objective Response Rate at 6 months using RECIST1.1 criteria","measure":"Objective response rate","timeFrame":"6 months"}],"registered_date":{"date":"2020-08-26","type":"ACTUAL"},"registry_last_updated":"2026-08-11","registry_url":"https://clinicaltrials.gov/study/NCT04526782","short_name":"ENCO-BRAF","short_name_basis":"registry_acronym","sponsor":"Intergroupe Francophone de Cancerologie Thoracique","start_date":{"date":"2021-01-19","type":"ACTUAL"},"study_design":"interventional, non randomized, parallel, phase2","study_ids":[{"id":"IFCT-1904","type":"sponsor_study_id"}],"study_type":"INTERVENTIONAL"}}}